128 related articles for article (PubMed ID: 24673265)
1. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
Samore WR; Gondi CS
Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
[TBL] [Abstract][Full Text] [Related]
2. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
3. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
[TBL] [Abstract][Full Text] [Related]
5. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
6. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
8. New biomarkers and targets in pancreatic cancer and their application to treatment.
Costello E; Greenhalf W; Neoptolemos JP
Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351
[TBL] [Abstract][Full Text] [Related]
9. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
Bisht S; Brossart P; Maitra A; Feldmann G
Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
[TBL] [Abstract][Full Text] [Related]
10. Twenty-one proteins up-regulated in human H-ras oncogene transgenic rat pancreas cancers are up-regulated in human pancreas cancer.
Yabushita S; Fukamachi K; Kikuchi F; Ozaki M; Miyata K; Sukata T; Deguchi Y; Tanaka H; Kakehashi A; Kawamura S; Uwagawa S; Wanibuchi H; Suzui M; Alexander DB; Tsuda H
Pancreas; 2013 Aug; 42(6):1034-9. PubMed ID: 23648844
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
[TBL] [Abstract][Full Text] [Related]
13. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Strimpakos AS; Saif MW
JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
[TBL] [Abstract][Full Text] [Related]
14. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
15. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
Matera R; Saif MW
Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
[TBL] [Abstract][Full Text] [Related]
17. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
18. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
19. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
[TBL] [Abstract][Full Text] [Related]
20. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]